&nbsp;

Dec 2025

Document

[PDF]

FrequentlyAskedQuestions-OCRSEERStat14.pdf

New

Dec 2025

Document

[PDF]

FrequentlyAskedQuestions-OCRSEERStat14-FR.pdf

New

Dec 2025

Regimen

ALEC

Cancer Type:

Lung,

Non-Small Cell

Intent: Palliative

Funding:

Exceptional Access Program

alectinib - Treatment of ALK-positive locally advanced or metastatic non-small cell lung cancer, according to specific criteria

Drugs Used:

alectinib

Quick Link(s):

Regimen Monograph

Dec 2025

Regimen

ASCI

Cancer Type:

Hematologic,

Leukemia - Chronic Myeloid (CML)

Intent: Palliative

Funding:

Exceptional Access Program

asciminib - For the treatment of Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase, based on criteria

Drugs Used:

asciminib

Quick Link(s):

Regimen Monograph

Dec 2025

Drug

acalabrutinib

Other Name(s): Calquence®

Quick Link(s):

Dec 2025

Drug

abemaciclib

Other Name(s): Verzenio®

Quick Link(s):

Dec 2025

Drug

anastrozole

Other Name(s): Arimidex®

Quick Link(s):

Dec 2025

Regimen

ACAL

Cancer Type:

Hematologic,

Leukemia - Chronic Lymphocytic (CLL)

Intent: Palliative

Funding:

Exceptional Access Program

acalabrutinib - For the treatment of adult patients with chronic lymphocytic leukemia (CLL), based on criteria

Drugs Used:

acalabrutinib

Quick Link(s):

Regimen Monograph

Dec 2025

Drug

atezolizumab

Other Name(s): Tecentriq™

Quick Link(s):

Jul 2025

Regimen

ABVD

Cancer Type:

Hematologic,

Lymphoma - Hodgkin

Intent: Curative

Drugs Used:

Quick Link(s):

Regimen Monograph, Patient Info Sheet

Feb 2026

Regimen

FRUQ

Cancer Type:

Gastrointestinal,

Colorectal

Intent: Palliative

Funding:

Exceptional Access Program

fruquintinib - For the treatment of metastatic colorectal cancer according to specific criteria

Drugs Used:

fruquintinib